SCHEMBL17902845

SCHEMBL17902845

CC(C)(C)c1ccc(-c2ccc3c(c2)CN(C(=N)N)CC3)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMPRSS2 O15393 7/20 0.52
HTR1A P08908 1/20 0.52
ADRA2A P08913 1/20 0.52
CYP2D6 P10635 1/20 0.52
MAOA P21397 1/20 0.52
SLC6A2 P23975 1/20 0.52
LMNA P02545 1/20 0.47
THRB P10828 1/20 0.47
TSHR P16473 1/20 0.47
PMP22 Q01453 1/20 0.47
HSD17B10 Q99714 1/20 0.47
F10 P00742 9/20 0.45
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
NR1H2 P55055 1/20 0.41
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19657600 0.81 ESR1 (0.46) KDM4EMEN1MAPTMAPK1KMT2A
SCHEMBL17894504 0.77 NR1H2 (0.47) KDM4EMEN1MAPTMAPK1KMT2A
SCHEMBL1648408 0.76 TMPRSS2 (0.63) TMPRSS2HTR1AADRA2ACYP2D6MAOA
Trifluoroacetic Acid SCHEMBL17894529 0.73 NR1H2 (0.42) KDM4EMEN1MAPTMAPK1KMT2A
SCHEMBL1648407 0.73 TMPRSS2 (0.63) TMPRSS2HTR1AADRA2ACYP2D6MAOA
Guanisoquin SCHEMBL2109074 0.73 TMPRSS2 (0.63) TMPRSS2HTR1AADRA2ACYP2D6MAOA
SCHEMBL8544496 0.73 TMPRSS2 (0.63) TMPRSS2HTR1AADRA2ACYP2D6MAOA
SCHEMBL19639431 0.71 NR1H2 (0.41) KDM4EMEN1MAPTMAPK1KMT2A
SCHEMBL10256437 0.71 NOTUM (0.59) F10KDM4EMEN1MAPTMAPK1
SCHEMBL14101113 0.70 ESR1 (0.68) KDM4EMEN1MAPTMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170342025-A1 ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS THE UNIVERSITY OF BATH (GB) 2017-11-30 US disclosed
US-20170342025-A1 ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS THE UNIVERSITY OF BATH (GB) 2017-11-30 US disclosed
US-20170342025-A1 ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS THE UNIVERSITY OF BATH (GB) 2017-11-30 US disclosed
WO-2016108045-A2 ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS SWANSEA UNIVERSITY (GB) 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342025-A1 ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS ZYX, MPO, CFB TMPRSS2 4294/4885HTR1A 4683/4885ADRA2A 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.